A clinical trial is a research study designed to evaluate the safety and effectiveness of new cancer treatment options. This type of research improves the treatment of cancer. As a result of these trials, cancer survival rates have increased, quality of life has improved and side effects have decreased for many patients.

Our Current Trials

BREAST

Locally advanced ER (+) HER2neu Neg

CO44657: A phase III, randomized, open-label study evaluating efficacy and safety of Giredestrant compared with Fulvestrant, both combined with a CDK4/6 Inhibitor, in patients with estrogen receptor positive, Her2-negative advanced breast cancer with resistance to prior adjuvant endocrine therapy.

Advanced with a PIK3CA Mutation

PIKALO-2 J6M-MC-JSGD: Protocol Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+, HER2- Advanced Breast Cancer with a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer

BLOOD DRAW

EXACT-SCIENCES

2021-05: Whole blood and tumor tissue specimens from subjects who either have a diagnosis of cancer or recurrent cancer to evaluate biomarkers.

PROSTATE

NRG-GU008: *INNOVATE: INtensifying treatment for NOde positive prostate cancer by VArying the hormonal ThErapy Randomized Phase III Trial incorporating apalutamide and advanced imaging into salvage treatment for patients with node positive prostate cancer after radical prostatectomy.

RARE GENITOURINARY CANCER

A031072:   A phase II study of Ipilimumab, Cabozantinig and Nivolumab in rare Genitourinary Cancer (ICONIC)

  • Cohort A: Small cell carcinoma/neuroendocrine of the bladder)
  • Cohort C: Squamous cell carcinoma.
  • Cohort D: Plasmacytoid urothelial carcinoma.
  • Cohort H: Sarcomatoid urothelial carcinoma
  • Cohort J: non-prostate bone only metastatic GU tumors
  • Cohort L: Urethra carcinoma.

HEAD AND NECK

VERSATILE-3:: Phase III,
Open-Label, Randomized Study of PDS0101 Plus Pembrolizumab vs Pembrolizumab Alone in First Line Treatment of Immune Checkpoint Inhibitor (ICI) Naïve Subjects with Unresectable Recurrent and/or Metastatic (R/M) Human Papillomavirus 16 (HPV16)-Positive Head and Neck Squamous Cell Carcinoma (HNSCC) ON HOLD

LUNG

COPERNICUS: Phase 2, Open-Label, Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous
Amivantamab in Combination with Platinum-Based Chemo as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Cohort 1: Newly diagnosed previously untreated (1L)

KRASCENDO: A Phase III, Randomized, Open-Label study evaluating the efficacy and safety of Divarasib and Pembrolizumab versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in patients with previously untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

OTHERS

LUNDQUIST PT2PC (22-001522): Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life

BMS - CA2430001 A Phase 1 First-in-Human Study of BMS-986500 as Monotherapy in Advanced Solid Tumors and as Combination Therapy in CDK4/6 Inhibitor Pre-treated Advanced Breast Cancer

ELI LILLY. J2R-MC-YAAD Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants with Malignant Disease

New! BESPOKE. This is a prospective, multi-center, single arm study designed to collect data to clinically characterize biomarkers associated with Natera test(s) from participants diagnosed with Stage I to IV tumors, for whom standard of care Natera MRD testing has been ordered (such as Signatera, Signatera Genome, or Latitude).

How Can I Participate in a Clinical Trial?

We have a number of trials available and will offer one to you if appropriate. Keep in mind that most clinical trials have strict eligibility criteria to protect patients and provide the best chance for success.  Age,  gender, cancer type and prior treatments may be included in  the selection criteria.  That means not all patients are eligible for a clinical trial.

What are the phases of a Clinical Trial?

Phase I trials assess the safety of a new medication or treatment.

Phase II trials also assess the safety of a new medication or treatment, but often measure the effectiveness of those treatments as well.

Phase III trials measure the effectiveness and safety of a new medication or treatment compared to the existing best practice.

What if I Get a Placebo?

Cancer patients participating in clinical trials will always receive a treatment that is equivalent to, or possibly better than, the standard treatment.  Placebo trials are never used when there is a potentially effective therapy available. Your doctor and research team can explain the details of placebo-controlled trials to you during your office visits.

Will My Clinical Trial Work?

There’s no guarantee that your clinical trial will work. However, before every clinical trial starts, the designers of the trial must present evidence that convinces the Food and Drug Administration (FDA) that the trial is a logical treatment option.

Can I Quit My Clinical Trial?

Participation in clinical trials is completely voluntary. Every participant in a clinical trial signs an informed consent form that outlines the trial’s potential benefits and risks. During the trial, the research team will monitor you closely and help manage any side effects you may experience. You can decide to stop participating in the trial at any time.